XML 80 R69.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Commitments and Contingencies (Details) $ in Thousands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9 Months Ended | 18 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 22, 2022 lawsuit | May 11, 2022 case | Apr. 19, 2022 case | Apr. 11, 2022 case | Mar. 11, 2022 stockholder | Mar. 09, 2022 stockholder | Mar. 07, 2022 stockholder | Mar. 05, 2022 case | Mar. 04, 2022 stockholder | Mar. 02, 2022 case | Feb. 28, 2022 stockholder case | Feb. 24, 2022 stockholder | Dec. 24, 2021 USD ($) case | Dec. 16, 2021 USD ($) | Sep. 11, 2020 | Oct. 02, 2019 | Aug. 29, 2019 judge | Mar. 24, 2015 patent | Feb. 11, 2015 patent | Sep. 30, 2022 lawsuit case | Apr. 30, 2017 patent lawsuit
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits dismissed |  |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Claims settled |  |  |  |  |  |  |  |  |  |  |  |  | 27 |  |  |  |  |  |  |  |
Xtampza ER Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents listed in FDA Orange Book | patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 months |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  | 2
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2
PTAB duration for issuing decision |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |
Statutory period of proceedings |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18 months |  |  |  |  |  |
Xtampza ER Litigation | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PTAB extended duration for issuing decision |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 months |  |  |  |  |
Xtampza ER Litigation, District of Delaware |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 months |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |
Xtampza ER Litigation, District of Massachusetts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stay period before FDA can issue a final approval unless it is terminated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 months |  |  |
Number of patents allegedly infringed | patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |
Opioid Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 |
Number of lawsuits dismissed |  |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13 |
Number of lawsuits designated as Track One case | lawsuit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |
Litigation settlement, amount awarded to other party | $ |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,750 |  |  |  |  |  |  |  |
Claims settled |  |  |  |  |  |  |  |  |  |  |  |  | 27 |  |  |  |  |  |  |  |
Opioid Litigation | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount awarded to other party | $ |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,750 |  |  |  |  |  |  |  |
Opioid Litigation, Pennsylvania state court |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of cases still awaiting court sign-off |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Opioid Litigation, Massachusetts state court |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of cases still awaiting court sign-off |  | 13 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits dismissed | lawsuit | 13 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Multi-District Litigation (MDL) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 21 |
Number of lawsuits dismissed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |
Opioid-Related Request and Subpoenas |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreed to pay attorney general | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 185 |  |  |  |  |  |  |
Reimbursement of investigation cost of the attorney general | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 65 |  |  |  |  |  |  |
BDSI Acquisition Litigation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional cases filed |  |  |  |  |  |  |  | 2 |  | 2 | 2 |  |  |  |  |  |  |  |  |  |
Number of demand letters received from purported stockholders | stockholder |  |  |  |  | 4 | 4 | 3 |  | 4 |  | 3 | 3 |  |  |  |  |  |  |  |  |
Number of judge in panel | judge |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |

X
- Definition Initial duration for issuing its decision by PTAB. + References No definition available. + Details
Name: | coll_DurationForDecisionIssue
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended period for issuing its decision by PTAB. + References No definition available. + Details
Name: | coll_ExtendedDurationForDecisionIssue
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional cases filed. + References No definition available. + Details
Name: | coll_LossContingencyNumberOfAdditionalCasesFiled
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of demand letters received from purported stockholders. + References No definition available. + Details
Name: | coll_LossContingencyNumberOfDemandLettersReceivedFromPurportedStockholders
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The reimbursement of investigation cost incurred by the Attorney General. + References No definition available. + Details
Name: | coll_LossContingencyReimbursementOfInvestigationCost
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the stay period before the Federal Drug Administration (FDA) can issue final approval unless the stay is terminated. + References No definition available. + Details
Name: | coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of cases still awaiting court sign-off. + References No definition available. + Details
Name: | coll_NumberOfCasesStillAwaitingCourtSignOff
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of judge in panel who settled the case. + References No definition available. + Details
Name: | coll_NumberOfJudgeInPanel
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of lawsuits designated as Track One case. + References No definition available. + Details
Name: | coll_NumberOfLawsuitsDesignatedTrackOneCase
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of patents listed in FDA Orange Book + References No definition available. + Details
Name: | coll_NumberOfPatentsListedInFdaOrangeBook
Namespace Prefix: | coll_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Statutory period of proceedings. + References No definition available. + Details
Name: | coll_StatutoryPeriodOfProceedings
Namespace Prefix: | coll_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims dismissed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of claims settled. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyClaimsSettledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyLossInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationAtPennsylvaniaStateCourtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidLitigationAtMassachusettsStateCourtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_MultiDistrictLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_OpioidRelatedRequestAndSubpoenasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=coll_BdsiAcquisitionLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |